Science advisory board

Dr. Danuta Radzioch is a Professor at the McGill University Health Centre and McGill University, affiliated with the Centres for Translational Biology and Innovative Medicine. She is a member of the Infection and Immunity Global Health Axis and the Medical Genetics and Genomics Axis. Her research focuses on molecular biology, host–pathogen interactions, inflammatory regulation, and translational medicine.

Her laboratory has developed and characterized multiple animal models, including cystic fibrosis lung disease, allergic asthma, airway hyperresponsiveness and atopy, and colon cancer. These studies have led to the identification of molecular signatures of chronic lung diseases, candidate genes regulating airway hyperresponsiveness and allergic asthma, and novel pharmacological strategies to normalize dysregulated inflammatory responses and lipid metabolism in severe infections, chronic allergic conditions, and acute injuries.

A Fulbright Scholar, Dr. Radzioch has received numerous prestigious awards and research grants from Canadian and international funding agencies. She serves on editorial boards, scientific advisory committees, and grant review panels, and is the co-author of numerous scientific publications, book chapters, and patents. Her work reflects a strong commitment to translational research, bridging fundamental molecular discoveries with preclinical development and clinical applications.

Dr. Petr Kocis is a former Global Head of Exploratory Chemistry at AstraZeneca within Global Enabling Sciences & Technologies. Over more than two decades, he has played a leading role in drug discovery research across oncology, immunodeficiencies, and asthma, holding senior scientific and leadership positions at Hoechst-Marion-Roussell, Zeneca Pharmaceuticals, and AstraZeneca.

Dr. Kocis is a pioneer in combinatorial chemistry and chemical library design. At Zeneca Pharmaceuticals, he co-founded the U.S. Chemical Technologies group, establishing a multidisciplinary Global Enabling Science & Technology platform and advancing novel technologies that were successfully industrialized across multiple therapeutic areas. He also contributed to defining the medicinally relevant chemical space of the AstraZeneca compound collection.

He is a recipient of the Zeneca R&D Director’s Award for Creativity and Innovation and the Merck Henry Christian Award for Excellence in Research. Dr. Kocis is the founding Editor-in-Chief of Current Drug Discovery Technologies, serves on several editorial boards and scientific advisory boards, and is the author or co-author of numerous scientific publications, book chapters, and patents. His research interests focus on modern medicinal chemistry, innovative drug discovery technologies, chemical and biological space mapping, and data visualization.

Dr. Marek Svoboda is clinical oncologist, internationally recognized expert in cancer biomarkers and cancer genetics. His research interests include various aspects of pathogenesis and clinical-labortory characteristics of breas, colorectal ad rare cancers. He was involved in multiple clinical trials in oncology and is aware of Czech biomedical research landscape. More Information here.